Loading clinical trials...
Loading clinical trials...
A Decentralized, Randomized Interventional Study to Evaluate the Impact of an Over-the-Counter Magnolia Officinalis Oral Supplement on Blood Biomarkers of Immune Activation in Subjects With Psoriasis
Conditions
Interventions
Oral supplement containing 200mg Magnolia officinalis bark extract
Placebo
Locations
1
United States
Decentralized Study Coordinating Center
Englewood, New Jersey, United States
Start Date
March 1, 2026
Primary Completion Date
September 1, 2028
Completion Date
September 1, 2029
Last Updated
March 13, 2026
NCT07474792
NCT06857942
NCT06979453
NCT07449234
NCT07116967
NCT07250802
Lead Sponsor
Sirt3 LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions